News
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
28 Mar 24
News, Price Target, Analyst Ratings
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
27 Mar 24
Earnings, News
Orchestra BioMed Demonstrates Strength Of Cardiovascular Pipeline With Virtue SAB And AVIM Therapy Presentations At CRT 2024 Annual Meeting
13 Mar 24
Biotech, News, General
Orchestra BioMed Announces Presentation Of Results From Clinical Study Demonstrating Hemodynamic Effects Of AVIM Therapy In Hypertensive Pacemaker Patients
6 Mar 24
Biotech, General
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction In 24-Hour Ambulatory Systolic Blood Pressure In Hypertensive Pacemaker Patients Treated With AVIM Therapy For Over 3 Years
26 Feb 24
Biotech, News, General
Press releases
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
27 Mar 24
Earnings, Press Releases
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
13 Mar 24
Health Care, Press Releases
Orchestra BioMed to Participate in Upcoming Investor Conferences
7 Mar 24
Press Releases
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
6 Mar 24
Press Releases